MG-K10 in Pediatric Atopic Dermatitis (6-12 Years)

November 12, 2026 updated by: Shanghai Mabgeek Biotech.Co.Ltd

A Phase Ib/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MG-K10 Humanized Monoclonal Antibody Injection in Pediatric Patients Aged 6 to 12 Years With Moderate to Severe Atopic Dermatitis

A Phase Ib/II Study of MG-K10 in Pediatric Patients (6-12 Years) with Moderate to Severe Atopic Dermatitis

Primary Objective:

To evaluate the safety of MG-K10 humanized monoclonal antibody injection in pediatric patients with moderate-to-severe atopic dermatitis (AD).

Secondary Objectives:

To evaluate the pharmacokinetic (PK) characteristics, preliminary efficacy, pharmacodynamic (PD) characteristics, and immunogenicity of MG-K10 humanized monoclonal antibody injection in pediatric patients with moderate-to-severe AD.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

24

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Shanghai, China
        • Tower 5,No.34,Chunxiao Road No.122 Pudong District, Shanghai, 201203.p R. china
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 12 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Aged ≥6 years and <12 years (calculated based on the date of ICF signature), regardless of gender, with a baseline body weight ≥15 kg and <60 kg.
  2. Diagnosed with atopic dermatitis (AD) according to the American Academy of Dermatology (AAD) consensus criteria (2014), with a history of AD or eczema diagnosed for ≥6 months prior to screening (with disease onset defined as the date of first symptom appearance).
  3. Inadequate response to topical medications within 12 months prior to screening, or medically unsuitable for topical medication therapy.
  4. Participants and/or their parents or legal guardians voluntarily provide written informed consent. For participants aged ≥6 years and <8 years, signing an informed consent form is not required, but an assent form must be completed. Participants must be able to communicate effectively with the investigator and comply with protocol-required follow-up visits.

Exclusion Criteria:

  1. Unable to undergo subcutaneous injection
  2. Have other active skin diseases that may affect AD evaluation (such as psoriasis or lupus erythematosus);
  3. Have diseases that may require systemic glucocorticoid or immunosuppressant treatment;
  4. Patients with ocular diseases deemed unsuitable for enrollment by the investigator;
  5. Received allergen-specific immunotherapy within 6 months before dosing; Stopped all topical medications less than 2 weeks before dosing, including topical glucocorticoids, topical calcineurin inhibitors, antibiotic compound creams, topical TCM therapy;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: A:MG-K10 humanized monoclonal antibody injection

Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection

Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks.

Experimental: B:MG-K10 humanized monoclonal antibody injection

Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection

Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks.

Experimental: C:MG-K10 humanized monoclonal antibody injection

Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection

Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks.

Experimental: D:MG-K10 humanized monoclonal antibody injection

Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection

Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence and severity of adverse events
Time Frame: Up to Week 24

Incidence and severity of AEs, plus abnormality rates/severity of vital signs, physical examination, clinical laboratory tests, and 12-lead ECG.

Up to Week 24

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percent of Participants with Investigator's Global Assessment (IGA) 0/1 and ≥2-Point Improvement
Time Frame: Each assessment visit through Week 16

Proportion achieving IGA score 0 or 1 AND ≥2-point reduction vs. baseline

Each assessment visit through Week 16
Percent of Participants with ≥2-Point IGA Improvement
Time Frame: Through Week 16

Proportion with IGA reduction ≥2 points vs. baseline

Through Week 16
Percent of Participants Achieving EASI-50, EASI-75, or EASI-90
Time Frame: Through Week 16

Proportion with ≥50%/75%/90% EASI reduction vs. baseline

Through Week 16
Change in Lesion Body Surface Area (BSA)
Time Frame: Through Week 16

Change in lesion body surface area

Through Week 16

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

March 1, 2028

Study Registration Dates

First Submitted

October 27, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe